Combination treatment of anti-SEMA4D with anti-LAG3 or epigenetic modulator entinostat resulted in maximal tumor growth delay and 90% CR (p<0.0001).Pepinemab treatment was well tolerated in a Phase I trial in patients with advanced refractory solid tumors (NCT01313065). The gene discussed is LAG3; the disease is neoplasm.